肾脏功能磁共振成像与CKD患者eGFR变化的关系
本研究基于COMBINE试验的122名eGFR 20-45 ml/min/1.73 m²的CKD患者,探索性分析基线扩散加权和血氧水平依赖MRI生物标志物与eGFR下降的关联。结果显示基线皮质ADC与eGFR年斜率相关,但校正白蛋白尿后不再显著;R2*无显著关联,且MRI指标在12个月内保持稳定。
要点
- 基线皮质ADC较高与eGFR年下降斜率较缓相关,但校正白蛋白尿后关联减弱。
- 基线R2*与eGFR变化无显著关联。
- 肾脏功能MRI生物标志物在12个月内保持稳定。
核心结论
- 基线皮质ADC与eGFR随时间变化相关,但该关联不独立于白蛋白尿。
- 肾脏功能MRI生物标志物在1年内保持稳定。
研究设计与样本
- 探索性研究,纳入COMBINE试验中122名eGFR 20-45 ml/min/1.73 m²的CKD患者。
- COMBINE为多中心、随机、双盲、12个月、四组平行试验,比较烟酰胺和碳酸镧与安慰剂。
- 获取基线扩散加权和血氧水平依赖MRI;87名参与者有12个月随访MRI数据。
主要发现
- 平均基线eGFR为32±9 ml/min/1.73 m²,平均年eGFR斜率为-2.3(95%CI -3.4至-1.1)ml/min/1.73 m²/年。
- 校正基线协变量后,基线ADC每增加1个标准差,年eGFR斜率差异为1.3(95%CI 0.1至2.5)ml/min/1.73 m²/年,ADC×时间交互P=0.04。
- 进一步校正白蛋白尿后,该差异为1.0(95%CI -0.1至2.2)ml/min/1.73 m²/年,ADC×时间交互P=0.08。
- 基线R2*与eGFR变化无显著关联。
- 87名有随访MRI的参与者中,ADC和R2*在12个月内稳定,组内相关系数分别为0.71和0.68。
临床怎么用
- 基线皮质ADC可能有助于识别CKD进展风险,但需考虑白蛋白尿的影响。
- 肾脏功能MRI生物标志物在1年内稳定,或可用于纵向监测。
局限性
- 探索性研究,样本量有限。
- ADC与eGFR变化的关联不独立于白蛋白尿。
- 仅87名参与者有随访MRI数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Kidney functional magnetic resonance imaging (MRI) requires further investigation to enhance the noninvasive identification of patients at high risk of CKD progression. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this exploratory study, we obtained baseline diffusion-weighted and blood oxygen level-dependent MRI in 122 participants of the CKD Optimal Management with Binders and Nicotinamide trial, which was a multicenter, randomized, double-blinded, 12-month, four-group parallel trial of nicotinamide and lanthanum carbonate versus placebo conducted in individuals with eGFR 20-45 ml/min per 1.73 m2. Lower values of apparent diffusion coefficient (ADC) on diffusion-weighted MRI may indicate increased fibrosis, and higher values of relaxation rate (R2*) on blood oxygen level-dependent MRI may represent decreased oxygenation. Because there was no effect of active treatment on eGFR over 12 months, we tested whether baseline kidney functional MRI biomarkers were associated with eGFR decline in all 122 participants. In a subset of 87 participants with 12-month follow-up MRI data, we evaluated whether kidney functional MRI biomarkers change over time. RESULTS: Mean baseline eGFR was 32±9 ml/min per 1.73 m2, and mean annual eGFR slope was -2.3 (95% confidence interval [95% CI], -3.4 to -1.1) ml/min per 1.73 m2 per year. After adjustment for baseline covariates, baseline ADC was associated with change in eGFR over time (difference in annual eGFR slope per 1 SD increase in ADC: 1.3 [95% CI, 0.1 to 2.5] ml/min per 1.73 m2 per year, ADC×time interaction P=0.04). This association was no longer significant after further adjustment for albuminuria (difference in annual eGFR slope per 1 SD increase in ADC: 1.0 (95% CI, -0.1 to 2.2) ml/min per 1.73 m2 per year, ADC×time interaction P=0.08). There was no significant association between baseline R2* and change in eGFR over time. In 87 participants with follow-up functional MRI, ADC and R2* values remained stable over 12 months (intraclass correlation: 0.71 and 0.68, respectively). CONCLUSIONS: Baseline cortical ADC was associated with change in eGFR over time, but this association was not independent of albuminuria. Kidney functional MRI biomarkers remained stable over 1 year. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: CKD Optimal Management with Binders and Nicotinamide (COMBINE), NCT02258074.
引用
- Srivastava A, Cai X, Lee J, et al. Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clin J Am Soc Nephrol. 2020. PMID: 32345747. doi:10.2215/CJN.13201019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。